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Amniotic fluid stem cells (AFSCs) are characterized in vivo by a unique niche guarantying their homeostatic role in the body.
Maintaining the functionality of stem cells ex vivo for clinical applications requires a continuous improvement of cell culture
conditions. Cellular redox status plays an important role in stem cell biology as long as reactive oxygen species (ROS)
concentration is finely regulated and their adverse effects are excluded. The aim of this study was to investigate the protective
effect of two antioxidants, sulforaphane (SF) and epigallocatechin gallate (EGCG), against in vitro oxidative stress due to
hyperoxia and freeze-thawing cycles in AFSCs. Human AFSCs were isolated and characterized from healthy subjects. Assays of
metabolic function and antioxidant activity were performed to investigate the effect of SF and EGCG cotreatment on AFSCs.
Real-time PCR was used to investigate the effect of the cotreatment on pluripotency, senescence, osteogenic and adipogenic
markers, and antioxidant enzymes. Alkaline phosphatase assays and Alizarin Red staining were used to confirm osteogenic
differentiation. The cotreatment with SF and EGCG was effective in reducing ROS production, increasing GSH levels, and
enhancing the endogenous antioxidant defences through the upregulation of glutathione reductase, NAD(P)H:quinone
oxidoreductase-1, and thioredoxin reductase. Intriguingly, the cotreatment sustained the stemness state by upregulating
pluripotency markers such as OCT4 and NANOG. Moreover, the cotreatment influenced senescence-associated gene markers in
respect to untreated cells. The cotreatment upregulated osteogenic gene markers and promoted osteogenic differentiation
in vitro. SF and EGCG can be used in combination in AFSC culture as a strategy to preserve stem cell functionality.
1. Introduction
Amniotic fluid represents a promising source of cells and is
free of ethical issues for regenerative medicine, including
cell-based [1] and cell-free [2, 3] therapy. Human amniotic
fluid stem cells (AFSCs) resemble different features from
both embryonic stem cells (ESCs) and mesenchymal stro-
mal/stem cells (MSCs). AFSCs have a valuable stemness
profile since they express ESC-associated pluripotency
markers such as OCT4 [4] NANOG [5], and SOX2 [6].
On the other hand, they share with MSCs with the absence
of tumorigenicity and display a great immunomodulatory
activity [7]. A substantial obstacle in producing clinical
grade stem cells is the need for GMP culture conditions that
must be xenofree during cryopreservation and postthawing
of the cells. Unfortunately, AFSCs, in comparison to other
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MSC sources, are isolated in a relatively low number and
need to be expanded prior and after their banking for clini-
cal trials [6]. Moreover, freshly isolated stem cells are
exposed to artificial physicochemical environments, quite
different from those present in vivo, that can lead to a loose
of the original functionality of the cells. Indeed, potential
stem cell self-renewal and differentiation are critically regu-
lated in vivo by oxygen and ROS concentrations that charac-
terize their niche. Low levels of ROS are involved in
physiological processes as proliferation and lineage specifi-
cation; meanwhile, excessive levels of oxygen cause them a
detrimental oxidative stress. In vitro cell cultures experience
an atmospheric oxygen tension that is much higher than
that found in tissues like bone marrow [8], umbilical cord
blood [9], liver, and lung [10]. Oxygen is barely measurable
in amniotic liquid [11]. Particularly, stem cells in vivo are
located in niches where oxygen tension is extremely low
(1-4%) [12] and hypoxic environments support the undiffer-
entiated state of the stem cell [13, 14]. Although the organ-
isms possess complex antioxidant systems to counteract
ROS deleterious effects, it is unlikely that they are able to
face the abnormal oxygen tension observed in vitro. More-
over, cryopreservation and thawing further increase ROS
levels exacerbating oxidative stress in vitro [15]. To harness
the robust therapeutic potential of AFSCs, a consistent and
economical method to fight the deleterious effect of ROS
induced by in vitro environment is essential. In this context,
natural dietary compounds with antioxidant activity are
optimal candidates to be included in stem cell culture proto-
cols because of their safety and their ability to control oxida-
tive stress. ARE-gene battery activated by Nrf2, the major
stress response regulator evolved by mammalian cells [16],
has been demonstrated to be induced by sulforaphane (SF)
in different cell types [17, 18] and by epigallocatechin gallate
(EGCG) [19] in MSCs, too [20]. In this study, we evaluated
the effect of a combined supplementation with SF and
EGCG on replicative capacity, redox state, senescence, and
stemness of human AFSCs.
2. Materials and Methods
2.1. Materials. The materials used include alpha-modified
eagle medium (αMEM), L-glutamine, penicillin/streptomy-
cin, Accutase, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-
tetrazolium bromide (MTT), dimethyl sulfoxide (DMSO),
EGCG, 2′-7′-dichlorodihydrofluorescein diacetate (DCFH-
DA), monochlorobimane (MCB), paraformaldehyde 4%
(PF 4%), 5-bromo-4-chloro-3-indolyl phosphate-Nitro Blue
Tetrazolium (BCIP/NBT®) Liquid Substrate System, Alizarin
Red staining, Senescence Cells Histochemical Staining Kit,
protease inhibitor cocktail, rabbit anti-β-actin, primers
listed in Table 1 (Sigma Chemical, St. Louis, USA), D,L-
sulforaphane, SF (LKT Laboratories, Minneapolis, USA),
fetal bovine serum (FBS) (EuroClone), Prestoblue®, Stem-
Pro® Osteogenesis Differentiation Kit (Thermo Scientific,
Waltham, USA), Alkaline Phosphatase Assay Kit (Abcam,
Cambridge, UK), RNeasy Mini kit (Qiagen, Germantown,
USA), iScript cDNA Synthesis Kit, SsoAdvanced Universal
SYBR Green Supermix Kit (Bio-Rad, Hercules, USA),
Supersignal substrate chemiluminescence detection kit
(Pierce, Rockford, USA), Immobilon-P membranes (Milli-
pore, Waltham, USA), rabbit anti-p16 (Abcam, Cambridge,
UK), and mouse anti-pH2A (Millipore, CA, USA).
All other chemicals of the highest analytical grade were
purchased from Sigma Chemical, unless otherwise stated.
2.2. Cell Isolation and Culture. Human amniotic fluid was
collected and processed as previously reported [21]. Human
AFSCs were isolated as previously reported [4]. Briefly,
amniocentesis cultures were harvested by trypsinization
and subjected to c-Kit immunoselection by MACS technol-
ogy (Miltenyi Biotec). Growth culture media are αMEM
supplemented with 20% of FBS, 2mM L-glutamine,
100U/ml penicillin, and 100μg/ml streptomycin. Cells were
passaged once or twice in a week, not subcultured above
1 : 3 ratio.
During the preamniocentesis interview, pregnant women
were informed about the purpose of the study and any related
risks. The informed consents were obtained, in accordance
with the Italian law and the guidelines of the ethics commit-
tee (protocol 2015/0004362 of 02.24.2015). Informed con-
sent, as well as all documentation relating to the invasive
procedure, was signed by the pregnant women and by a spe-
cialist before continuing the exam.
2.3. MTT Assay. AFSCs were seeded in 96-well plates at a
density of 10000 cells/well (day 0) in 200μl of a culture
medium, 4 replicates for each condition. At the end of each
experiment, 0.5mg/ml MTT was added and incubated for
1.5 h at 37°C. After incubation, MTT solution was removed
and DMSO was added to solubilize the formazan salts. The
absorbance was measured at λ = 595 nm using a microplate
spectrophotometer (VICTOR3 V Multilabel Counter; Perki-
nElmer, Wellesley, MA, USA).
2.4. ROS Detection. To evaluate intracellular ROS levels,
dichlorodihydrofluorescein diacetate (DCFH-DA) assay
was performed as previously described [22]. Cells were
seeded in a 96-well plate at density of 10000 cells/cm2, 4
replicates for each condition, treated with EGCG and SF
for 72 hours soon after thawing, otherwise chronically
during expansions. Cell culture medium was removed,
and the 5μM DCFH-DA was incubated in αMEM 1%
FBS without phenol red for 30min, at 37°C and 5%
CO2. The cell culture plate was washed with PBS, and
fluorescence of the cells was read at 485nm (excitation)
and 535nm (emission) using the VICTOR multilabel plate
reader (PerkinElmer).
2.5. PrestoBlue® Assay. Cell viability PrestoBlue® reagent is a
ready-to-use resazurin-based solution that functions as a cell
health indicator by using the reducing power of living cells.
PrestoBlue® reagent was prepared in growth culture media
without phenol red. AFSCs were seeded at 10000 cells/well
in 96-well plates (day 0) in 200μl of a culture medium, 4 rep-
licates for each condition. At 24 h and 72 h, the cell culture
medium was replaced with 100μl of PrestoBlue working
solution and incubated at 37°C and 5% CO2. After 2 hours,
the incubated PrestoBlue volumes were collected in a new
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96-well plate and the cells were refeed with a fresh culture
medium. The absorbancewas read atλ = 570 nm (experimen-
tal) and λ = 600 nm (reference wavelength for normalization)
using the VICTOR multilabel plate reader (PerkinElmer).
2.6. Population Doublings. AFSCs were subcultured until
75% of confluence. Cells beyond confluence were detached
usingAccutase solution. Cell suspension aliquots were stained
in trypan blue and counted by Countess system (Thermo
Fisher, Waltham, USA). Diluted cell suspension was seeded
again in T25 flasks. To calculate cumulative population dou-
bling (cPD), the following formula was applied to all samples
for each experimental group:
PD = log10NH − log10NSlog102
, 1
where PD is population doubling, NS is the cell number at
seeding, and NH is the cell number at harvest. To calculate
the cumulative number of population doublings (cPDs), the
PDs determined for each passage were summed.
2.7. Glutathione Detection. To evaluate reduced GSH levels,
monochlorobimane (MCB) assay was performed as previ-
ously reported [23]. AFSCs were seeded in a 96-well plate
at a density of 15000 cells/cm2, 4 replicates for each condi-
tion, treated for 72h soon after thawing, otherwise chroni-
cally during expansion. Cell culture medium was removed,
and 50μM MCB was incubated in αMEM without phenol
red supplemented with 1% FBS for 30min, at 37°C and
5% CO2. The cells were washed in PBS, and fluorescence
of the cells was measured at 355 nm (excitation) and
460 nm (emission) using the VICTORmultilabel plate reader
(PerkinElmer). Cellular autofluorescence was subtracted as a
Table 1: Primers used in RT-PCR. ∗Internal normalizer.
Gene Sequence RefSeq accession no.
RPS18∗
Fw CAGAAGGATGTAAAGGATGG
NM_022551
Rv TATTTCTTCTTGGACACACC
GAPDH∗
Fw ACAGTTGCCATGTAGACC
NM_002046
Rv TTGAGCACAGGGTACTTTA
NQO1
Fw AGTATCCACAATAGCTGACG
NM_000903
Rv TTTGTGGGTCTGTAGAAATG
GR
Fw GACCTATTCAACGAGCTTTAC
NM_000637
Rv CAACCACCTTTTCTTCCTTG
TR
Fw AGACAGTTAAGCATGATTGG
NM_001093771
Rv AATTGCCCATAAGCATTCTC
NANOG
Fw CCAGAACCAGAGAATGAAATC
NM_024865
Rv TGGTGGTAGGAAGAGTAAAG
SOX2
Fw ATAATAACAATCATCGGCGG
NM_003106
Rv AAAAAGAGAGAGGCAAACTG
OCT4
Fw AGAGAAAGCGAACCAGTATC
NM_002701.5
Rv TTACAGAACCACACTCGG
β-gal
Fw GACAGTACCAGTTTTCTGAG
NM_000404
Rv ATAGACTCTTTCTCTAGCAGC
p16
Fw AGCATGGAGCCTTCG
NM_000077
Rv ATCATGACCTGGATCGG
RUNX2
Fw GCAGTATTTACAAGAGGG
NM_001015051
Rv TCCCAAAAGAAGTTTTGCTG
OPN
Fw CATCTCAGAAGCAGAATCTC
NM_001251830
Rv GAAGGGTCTCTTGTTTAAAGTC
OSC
Fw TTCTTTCCTCTTCCCCTTG
NM_199173
Rv CCTCTTCTGGAGTTTATTTGG
PPARγ
Fw AAAGAAGCCAACACTAAACC
NM_138712
Rv TGGTCATTTCGTTAAAGGC
ADPQ
Fw GGTCTTATTGGTCCTAAGGG
NM_ 001177800
Rv GTAGAAGATCTTGGTAAAGCG
FABP4
Fw CAAGAGCACCATAACCTTAG
NM_ 001442
Rv CTCGTTTTCTCTTTATGGTGG
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background using the values of the wells not incubated with
the probe.
2.8. SA-β-galactosidase Assay. Expression of senescence-
associated β-galactosidase (SA-β-gal) in AFSCs was analysed
using Senescence Cells Histochemical Staining Kit, according
to the manufacturer’s instructions. Increased β-galactosidase
expression detected by blue coloured staining has been
reported to increase in senescent cells [24]. Briefly, subcon-
fluent AFSCs were washed in PSB and fixed for 4min.
Staining solution was incubated at 37°C overnight. SA-β-
gal-positive stained cells were examined under the light
microscope with 10x magnification. Representative pictures
from random fields were acquired by a colour camera. For
quantitative analysis, at least 150 total cells from each con-
dition were counted across multiple fields. Percentages of
senescent cells vs. total cells were obtained based on the
counts by two operators.
2.9. In Vitro Osteogenesis. Osteogenesis induction was per-
formed with StemPro® Osteogenesis Differentiation Kit
according to the manufacturer’s instructions. Briefly, AFSCs
were plated on various substrates and cultured up to 2 days
before switching to differentiation medium. The cells were
subsequently cultured for 14 days replacing the medium
twice a week.
For alkaline phosphatase detection, after cell culture
medium removal, cells were washed in PBS and fixed for
10min in PF 4%. Cells were then washed in H2O; BCIP®/
NBT Liquid Substrate System was added, and cells were incu-
bated overnight at room temperature. Alkaline phosphatase
converts BCIP to a product that reduces NBT to a blue-
purple precipitate. Samples were finally washed in H2O.
For Alizarin Red staining, cells were washed in PBS and
fixed for 10min in PF 4%. Cells were then washed in H2O,
and 2% Alizarin Red solution was added for 30min at room
temperature. Red staining is indicative of calcium deposits.
Samples were finally washed in H2O. To quantify the Alizarin
Red S staining, samples were washed with PBS and then 10%
cetylpyridinium chloride was added and incubated for
20min to elute the stain. 10μl of this elution was added to
90μl of water and read at 485 nm using a spectrophotometer
(VICTOR multilabel plate reader, PerkinElmer) [25]. To
quantify the alkaline phosphatase, Alkaline Phosphatase
Assay Kit was used following the manufacturer’s instruction,
measuring absorbance at 390 nm using a spectrophotometer
(VICTOR multilabel plate reader, PerkinElmer).
2.10. Real-Time PCR. To evaluate the expression of antioxi-
dant enzymes, the cells were seeded in 6-well plates at 70%
confluence and treated with SF and EGCG and, after 6 hours,
RNA was extracted. To evaluate the levels of stemness and
senescence, the cells were gently thawed in complete growth
media and pelleted and split in treated and not treated sam-
ples. After 72 hours, RNA was extracted; alternatively, the
samples were expanded continuing to receive the treatment
or not. RNA was isolated using RNeasy Mini kit following
the manufacturer’s protocol. Starting from 1μg of the
extracted RNA, the cDNA was obtained using iScript cDNA
Synthesis Kit following the manufacturer’s protocol. Real-
time PCR was performed using SsoAdvanced Universal
SYBRGreen Supermix following the manufacturer’s protocol
(temperature). Real-time PCR reaction was carried out in a
total volume of 10μl loading 250ng of cDNA and 500nM
of each primer. The cDNA amplification was performed by
activating the polymerase for 30 s at 95°C, followed by 40
cycles of 5 s at 95°C and 30 s at 60°C. Primer sequences used
in this study are listed in Table 1. Normalized expression
levels were calculated relative to control cells according to
the 2−ΔΔCT method.
2.11. Immunofluorescence and Confocal Microscopy. For
immunofluorescence analysis, samples were processed as
previously described [6]. Confocal imaging was performed
by a Nikon A1 confocal laser scanning microscope. Primary
antibodies were raised against the following molecules:
mouse-pH2A and Rabbit-p16. The confocal serial sections
were processed with ImageJ software to obtain three-
dimensional projections. The image rendering was per-
formed by Adobe Photoshop software.
2.12. Western Blotting. Cell extracts were obtained as
described by Beretti et al. [21]. Briefly, subconfluent cells
were extracted by the addition of AT lysis buffer (20mM
Tris-Cl, pH7.0; 1% Nonidet P-40; 150mM NaCl; 10% glyc-
erol; 10mM EDTA; 20mM NaF; 5mM sodium pyrophos-
phate; and 1mM Na3VO4) and freshly added protease
inhibitor cocktail at 4°C for 30min. Lysates were sonicated,
cleared by centrifugation, immediately boiled in SDS sample
buffer, and centrifuged. Supernatants were loaded onto SDS-
polyacrylamide gel, blotted on Immobilon-P membranes,
and processed by western blot with the indicated antibodies,
detected by SuperSignal substrate chemiluminescence detec-
tion kit. Quantitation of the signal was obtained by chemilu-
minescence detection on a Kodak Image Station 440CF and
analysis with the Kodak 1D Image software. Primary anti-
bodies were raised against the following molecules: rabbit-
p16 and rabbit-β-actin.
2.13. Statistics. Statistical analysis and plot layout were
obtained by using GraphPad Prism® release 6.0 software.
Statistics performed are described in figure legends.
3. Results
3.1. EGCG and SF Effect on Cell Viability. SF or EGCG was
supplemented in the culture medium at concentrations rang-
ing from 1 to 10μM. After 3 days, cytotoxicity was evaluated.
Viability of cells treated with 1μM and 2μM SF was compa-
rable to untreated control cells, while higher concentrations
significantly reduced AFSC viability (Figure 1(a)). EGCG
treatment did not influence cell viability at any tested con-
centrations (Figure 1(b)).
3.2. SF and EGCG Treatments Reduce the Intracellular ROS
Level. As ROS are able to impair stem cell functionality
[15], we verified the effect of SF and EGCG treatment on
intracellular ROS level. Cells were treated with non-toxic
concentrations of SF or EGCG before DCFH-DA assay
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(Supplementary Materials, Figure S1). One and 2μM SF
significantly reduced the ROS level; meanwhile, only 10μM
EGCG was effective in reducing basal ROS levels. On the
basis of these results, to evaluate the potential additive
effect of the combined treatment with SF and EGCG, we
selected 1μM SF and 10μM EGCG for the cotreatment
(Figure 2(a)). Noteworthy, EGCG-SF cotreatment for 3 days
was able to significantly reduce the ROS level in respect to
cells treated with SF and EGCG alone. As the combination
of the two natural compounds was more effective than the
treatment with the single compounds, only the cotreatment
was utilized for the subsequent experiments. As thawing is
a critical event for stem cells due to hyperoxia and
subsequent ROS production [15], cells were cotreated soon
after thawing with SF and EGCG for 3 days before ROS
evaluation (Figure 2(b)). As we observed an increase in the
ROS level during cell passages, we evaluated the effect of a
chronic treatment. AFSCs were exposed to the cotreatment
starting from thawing until 25 d of culture (Figure 2(b)).
In agreement with the acute treatment, the long-term
treatment significantly reduced the intracellular ROS level.
3.3. EGCG and SF Cotreatment Does Not Affect Expansion
of AFSCs. Cells were cotreated with EGCG and SF, and
the metabolic activity was evaluated by PrestoBlue assay.
Interestingly, EGCG-SF treatment significantly increased
the metabolic rate in respect to control cells at 3 days
(Figure 3(a)). Cells chronically cotreated with EGCG and
SF were compared to untreated cells for population dou-
blings (PD) obtained by semiautomatic cell counting. The
chronic cotreatment of AFSCs with the antioxidants did
not increase cell numbers during AFSC expansion; indeed,
PDs from treated and not treated cells were comparable at
each time point (Figure 3(b)).
3.4. EGCG and SF Cotreatment Enhances the Antioxidant
Defence System. In order to investigate the effect of the
cotreatment on the endogenous antioxidant defence system,
cells were exposed to 1μM SF and 10μM EGCG and
GSH level and expression of GR, NQO1, and TR were eval-
uated (Figure 4). The GSH level were not influenced by a
3-day cotreatment (Figure 4(a)); nevertheless, it signifi-
cantly increased after a chronic treatment for 25 days
(Figure 4(b)). To evaluate antioxidant enzyme expression,
cells were cotreated with SF and EGCG and then RNA was
extracted and analysed by real-time PCR. Of note, the
cotreatment was able to significantly upregulate GR, TR,
and NQO1 (Figure 4(c)).
3.5. EGCG and SF Cotreatment Prolongs Stemness Markers
and Delays the Expression of Senescence Markers. To study
the effect of the cotreatment on stemness of AFSCs, gene
expression of markers associated to pluripotency state, such
as OCT4, NANOG, and SOX2 [26, 27], was evaluated by
real-time PCR. AFSCs treated immediately after thawing for
3 days showed significantly higher levels of OCT4, NANOG,
and SOX2 mRNAs, in comparison to untreated samples
(Figure 5). The chronic treatment of cells during expansion
influenced the expression ofOCT4 and alsoNANOG. Indeed,
cells at early and late passages showed a greater expression of
these two markers in comparison to the untreated controls
(Figure 5). Moreover, the cells expanded for consecutive pas-
sages were analysed by real-time PCR for the expression of
senescence-associated markers (Figures 6(a) and 6(b)). The
cells in the absence of treatment had a stronger increase in
the expression of p16 and β-gal, as consequence of passaging,
in comparison to the treated cells that showed only a limited
increase (Figures 6(a) and 6(b)). Cotreatment effect on p16
has also been confirmed by western blot analysis and immu-
nofluorescence (Figure 6(a)). SA-β-gal activity has been
reduced by the cotreatment, as shown in Figure 6(b). The
obtained results are consistent with the RT-PCR data. To
strengthen these observations, we evaluated senescence-
associated DNA damage foci (SDFs), a DNA damage
response marker (Figure 6(c)). Of note, cotreated cells pre-
sented a lower number of nuclei with phospho-histone 2A
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Figure 1: Viability of AFSCs treated with SF and EGCG. Cells were treated for 3 days with increasing concentrations of (a) SF or (b) EGCG.
Viability was measured by MTT assay, as reported in Materials and Methods. Each bar represents means± SEM of 3 independent
experiments. Data were analysed by one-way ANOVA followed by Bonferroni’s test. ∗∗∗∗p < 0 0001 with respect to CTRL.
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(pH2A) foci than control cells, confirming the antisenescence
effect of the cotreatment.
3.6. EGCG-SF Treatment Primes for Osteogenic Differentiation.
Since antioxidants can modulate differentiation of stem
cells [28], AFSCs treated with EGCG and SF were analysed
for lineage-specific master regulators of osteogenesis and
adipogenesis (Figure 7). A 9-day treatment significantly
upregulated the expression of osteogenic markers, such
as RUNX2, osteopontin (OPN), and osteocalcin (OSC),
unlike the expression of the adipogenic markers PPARγ
and adiponectin (ADPQ). Even if the cotreatment upregu-
lated the adipogenic marker fatty acid-binding protein 4
(FABP4), this slight modulation could not be considered
relevant from a biological point of view. To evaluate the effect
of SF and EGCG cotreatment on in vitro osteogenic
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Figure 2: Effect of AFSC treatment with SF and EGCG on the ROS intracellular level. (a) Cells were treated or cotreated for 3 days with 1μM
SF and 10 μMEGCG. ROS levels were evaluated by DCFH-DA fluorometric assay, as reported in Materials and Methods. Each bar represents
means± SEM of 3 independent experiments. Data were analysed by one-way ANOVA followed by Bonferroni’s test. ∗p < 0 05, ∗∗∗∗p < 0 0001
with respect to relative control. (b) Cells were cotreated for 3 days after their thawing or (c) chronically treated for 25 days. The ROS level was
evaluated by DCFH-DA fluorometric assay as reported in Materials and Methods. Each bar represents means± SEM of 3 independent
experiments. Data were analysed by one-way ANOVA followed by Bonferroni’s test. ∗p < 0 05, ∗∗∗∗p < 0 0001with respect to relative control.
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Figure 3: Effect of the cotreatment with SF and EGCG on AFSC viability and proliferation. (a) Cells were cotreated with SF and EGCG and
metabolic activity evaluated by PrestoBlue assay, as reported in Materials and Methods at 1 day and 3 days after treatment. Each bar
represents means± SEM of 3 independent experiments. Data were analysed by a Mann–Whitney test. ∗∗∗p < 0 001 with respect to control
cells. (b) Cells were cotreated chronically and expanded for 25 days in culture, and cPD was calculated as reported in Materials and
Methods. Each dot represents means of 3 independent experiments.
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Figure 4: Effect of the cotreatment with SF and EGCG on AFSC antioxidant defences. (a) Cells were cotreated for 3 days after thawing or (b)
chronically treated for 25 days. GSH levels were evaluated by MCB fluorimetric assay as reported in Materials and Methods. Each bar
represents means± SEM of 3 independent experiments. Data were analysed by a Mann–Whitney test. ∗∗∗∗p < 0 0001 with respect to the
control. (c) Effect of the treatment with SF and EGCG on the expression of GR, TR, and NQO1 in AFSCs. Cells were cotreated for 6 h
after thawing. Total RNA was isolated, and the mRNA, as expression of target genes, was quantified using RT-PCR normalized to
housekeeping gene as reported in Materials and Methods. Triplicate reactions were performed for each experiment. Each bar represents
mean± SEM of 3 independent experiments. Data were analysed by a Mann–Whitney test. ∗p < 0 05, ∗∗p < 0 01, and ∗∗∗∗p < 0 0001.
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Figure 5: Effect of AFSC cotreatment with SF and EGCG on stemness. Total RNA was isolated, and mRNA expression of target genes was
quantified using RT-PCR normalized to housekeeping genes as reported in Materials and Methods. Triplicate reactions were performed for
each experiment. Cells were cotreated for 3 days after thawing or cotreated chronically during AFSC expansion for 25 days, and OCT4,
NANOG, and SOX2 gene expression was analysed. Each bar represents the mean± SEM of 3 independent experiments. Data were
analysed by two-way ANOVA followed by Bonferroni’s test. ∗p < 0 05, ∗∗p < 0 01, ∗∗∗p < 0 001, and ∗∗∗∗p < 0 0001.
7Oxidative Medicine and Cellular Longevity
differentiation, osteogenic differentiation was induced sup-
plementing the differentiation medium with EGCG and
SF for 14 days. Interestingly, the cotreatment boosts up
osteogenic differentiation as confirmed by alkaline phospha-
tase assays (Figures 7(c) and 7(e)) and Alizarin Red staining
(Figures 7(d) and 7(f)).
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4. Discussion
In vivo stem cells reside in a hypoxic niche that preserves
MSC progenitor properties [29]; meanwhile, routinely,
in vitro culture of stem cells is performed in atmospheric oxy-
gen tension that leads to an abnormal production of ROS.
Moreover, freeze-and-thaw cycles also contribute to oxida-
tive stress [30]. The excess of intracellular ROS deeply
impacts on stem cell functionality, e.g., postthawing recovery,
proliferation, and differentiation ability [30]. To arm MSCs
against these stresses is a challenge for basic and clinical
research. Plant secondary metabolites carry out numerous
interactions, and many phytochemicals show a potent anti-
oxidant activity. Antioxidants may represent a tempting
strategy in order to limit the oxidative stress in vitro of
human stem cells. Nrf2-Keap1 is the most important stress
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Figure 7: Effect of cotreatment with SF and EGCG on osteogenic differentiation potential. (a) Effect of the treatment with SF and EGCG after
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response-related pathway [31], and among its activators, the
flavonoid EGCG and the isothiocyanate SF have gained a
great popularity and consideration mainly as chemopreven-
tive [32, 33] and cardioprotective agents [34, 35].
On the basis of these premises, we explored the effect of a
combined treatment with EGCG and SF on postthawing
recovery and expansion of human AFSCs. These two phyto-
chemicals were chosen since they possess different chemo-
physical properties (EGCG is more hydrophilic than SF)
and because they could modulate various cell pathways.
Many examples regarding the improving in protocols for
cryobiology of stem cells are based on single antioxidant sup-
plementation [36–38]. Our results show a higher efficacy of
the cotreatment with SF and EGCG against oxidative stress
in respect to the single antioxidant treatment. Importantly,
the synergic effect of EGCG and SF on oxidative stress was
observed after cell thawing, i.e., a time frame in which a burst
of unavoidable ROS impairs the cells.
As it has been recently highlighted a positive correlation
between GSH and stemness and general functionality in
MSCs [39], we checked GSH levels that resulted a significant
increase after a chronic cotreatment with the two antioxi-
dants. The TRX and GSH systems are the major cellular anti-
oxidant defence mechanisms, interacting with many cellular
survival pathways [40]. Interestingly, EGCG and SF cotreat-
ment upregulated both GR and TR, the antioxidant enzymes
that preserve TRX and GSH homeostasis. Moreover, our
data indicated an upregulation of another key antioxidant
enzyme, NQO1, involved in the production of hydroquinone
to counteract deleterious quinonic radical formation. Taken
together, our data suggest that EGCG and SF counteract
oxidative stress by enhancing the antioxidant defence sys-
tem in AFSCs.
As highlighted above, cryopreservation is an artificial
step that not rarely affects stem cell original features. In our
experimental protocol, after cell thawing, the cotreatment
with EGCG and SF induced the upregulation of the expres-
sion of pluripotency-associated markers such as OCT4,
NANOG, and SOX2, in respect to control untreated cells.
Thus, EGCG and SF may be proposed as “preservative”
agents for the self-renewal of MSCs, retarding their sponta-
neous decrease of pluripotency with passaging overtime.
Away from their in vivo niche, stem cells [41, 42] normally
undergo senescence. In this context, ROS were known to
contribute to senescence via specific pathways like the ones
modulated by p16 and p38 [43, 44]. The expressions of the
senescent markers were delayed in our experimental proto-
col. This antiaging effect is in agreement with the improved
stemness marker profile we observed after a chronic exposure
to EGCG and SF. These data suggest a reduced activation of
ROS-induced senescence pathways [44]. Indeed, both EGCG
[20] and SF [45] were shown to be involved in the repression
of senescence in vitro in MSCs. Many biological functions of
MSCs have been linked to microvesicles that act as paracrine
factors. As microvesicles mirror the parental cell characteris-
tics, delaying senescence could also preserve microvesicle
efficacy [46].
Multipotent AFSCs can be committed to mesenchy-
mal lineages, such as osteogenic and adipogenic lineage.
Osteogenesis and adipogenesis in MSCs are phenotypes
competing each other [47]. The pathways governing the oste-
ogenic and adipogenic differentiation are modulated by two
master regulators that are peroxisome proliferator-activated
receptor-γ (PPARγ) and runt-related transcription factor 2
(RUNX2). Inhibition of the adipogenesis specifically due to
SF [48] and EGCG [49, 50] or generally due to Nrf2 activa-
tion [51] was reported. Interestingly, during cell expansion,
chronic cotreatment counteracted OCT4 and NANOG phys-
iological decrease; meanwhile, SOX2, a repressor of mesoder-
mic differentiation [52], was comparable to control cells.
Moreover, the addition of EGCG [53–55] and SF [56] was
associated to a proosteogenic phenotype, so we investigated
the effect of their cotreatment in osteogenic differentiation.
A 9-day cotreatment promotes a proosteogenic profile in
AFSCs, as evidenced by the upregulation of RUNX2 and
other osteogenic markers like OSC and OPN. Thus, priming
AFSCs with EGCG and SF may be a stimulation step to trig-
ger osteogenic differentiation in vitro. Indeed, the expression
of the adipogenesis marker PPARγ, ADPQ, and FABP4 were
not influenced by the cotreatment, suggesting that SF and
EGCG do not affect adipogenic potential of AFSCs. Further-
more, samples were simultaneously cotreated and induced to
differentiate for 14 days towards osteogenic lineage and were
analysed by histochemistry. The cotreatment promoted the
osteogenesis commitment, as seen by ALP histochemical
staining and calcium deposition by Alizarin staining. Indeed,
the cotreatment increases calcium deposition during osteo-
genic differentiation; meanwhile, ALP activity decreases, as
expected, since during normal osteogenic differentiation,
there is an initial peak in ALP production followed by a sub-
sequent decrease as the cells mature and lay down mineral
[57]. In this way, the proposed SF and EGCG cotreatment
is at least compatible with osteogenic differentiation proto-
cols, an important concern for the use of AFSCs in bone
regenerative medicine and tissue engineering.
5. Conclusions
In summary, the number of cell passages, the maintenance of
the self-renewal capacity, and the ability to counteract the
external oxidative stress are critical key points to be consid-
ered for the quality control of AFSCs [58]. In our study,
EGCG and SF were proposed as alternative bioderived addi-
tives for prolonging lifespan of functional in vitro AFSCs
since a retained functionality is essential for enhancing the
therapeutic potential of this promising stem cell population.
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